Bifidobacterium longum as a delivery system for therapy: Selective localization and growth in hypoxic tumors

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 269-274

  Yazawa, Kazuyuki ^a   Fujimori, Minoru ^a   Amano, Jun ^a   Kano, Yasunobu ^b   Taniguchi, Shun'ichiro ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Anaerobic bacteria; Bifidobacterium longum; Cancer gene therapy; Hypoxia; Tumor targeting; Vector

Indexed keywords

GENE PRODUCT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BIFIDOBACTERIUM LONGUM; CANCER THERAPY; CELL HYPOXIA; CLONING VECTOR; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALIA; BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM LONGUM;

EID: 0034032620     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700122     Document Type: Article

References (24)

1. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and survey of existing data. Int J Radiat Oncol Biol Phys. 1984;10:695-712.
2. Vaupel PW, Hockel M. Oxygenation status of human tumors: a reappraisal using computerized pO2 histography. In: Vaupel PW, Kelleher DK, Gunderoth M, eds. Tumor Oxygenation. New York: Fischer-Verlag, Stuttgart; 1994:219-232.
3. Vaupel PW. Oxygenation of solid tumors in drug resistance in oncology. In: Teicher BA, ed. New York: Marcel Dekker; 1993:53-85.
4. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med. 1997;3:515-520.
5. Kimura NT, Taniguchi S, Aoki K. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res. 1980;40: 2061-2068.
6. Malmgren RA, Flanigan CC. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. 1955;15: 473-478.
7. Mitsuoka T. The human gastrointestinal tract. In: Wood BJB, ed. The Lactic Acid Bacteria; The Lactic Acid Bacteria in Health and Disease. London and New York: Applied Science; 1992:69-114.
8. Gorbach SL, Plaut AG, Nahas L, et al. Studies in intestinal microflora: microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology. 1967;53: 856-867.
9. Drasar BS, Shiner M, McLeod GM. Studies on the intestinal flora: the bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. Gastroenterology. 1969; 56:71-79.
10. Yasui H, Ohwaki M. Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J Dairy Sci. 1991;74:1187-1195.
11. Reddy BS, Rivenson A. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo [4,5-f] quinoline, a food mutagen. Cancer Res. 1993;53:3914-3918.
12. Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994;344:1046-1049.
13. Matsumura H, Takeuchi A, Kano Y. Construction of Escherichia coli-Bifidobacterium longum shuttle vector transforming B. longum 105-A and 108-A. Biosci Biotechnol Biochem. 1997;61:1211-1212.
14. Briggs M. The classification of lactobacili by means of physiological tests. J Gen Microbiol. 1953;9:234-248.
15. Natori Y, Kano Y, Imamoto F. Characterization and promoter selectively of Lactobacillus acidophilus RNA polymerase. Biochimie. 1988;70:1765-1774.
16. Lemmon MJ, van Zijl P, Fox ME, et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 1997;4:791-796.
17. Fox ME, Lemmon MJ, Mauchline ML, et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 1996;3:173-178.
18. Minton NP, Mauchline ML, Lemmon MJ, et al. Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol Rev. 1995;17:357-364.
19. Saltzman DA, Heise CP, Hasz DE, et al. Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. Cancer Biother Radio. 1996;11:145-153.
20. Low KB, Ittensohn M, Le T, et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat Biotechnol. 1999;17:37-41.
21. Carey RW, Holland JF, Whang HY, et al. Clostridial oncolysis in man. Eur J Cancer. 1967;3:37-46.
22. Hone DM, Tacket CO, Harris AM, et al. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest. 1992;90:412-420.
23. Tacket CO, Hone DM, Curtiss R III, et al. Comparison of the safety and immunogenicity of δ aroC δ aroC and δ cya δ crp Salmonella typhi strains in adult volunteers. Infect Immun. 1992;60:536-541.
24. Argnani A, Leer RJ, van Luijk N, et al. A convenient and reproducible method to genetically transform bacteria of the genus Bifidobacterium. Microbiology. 1996;142:109-114.